Dry Eye

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss their preferred clinical diagnostic tools and tests to evaluate patients for dry eye disease (DED) and strategies for educating patients on their results.

Experts offer their clinical perspectives on the use of dry eye questionnaires as a method of screening for dry eye disease (DED).

Experts discuss the impact of dry eye disease (DED) on coexisting ocular conditions and their clinical experience managing these patients.

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss the prevalence of dry eye disease (DED) and how it can impact the quality of life for patients.

Influencers on TikTok claim the vegetable oil promotes eye health. However, ophthalmologists say the risks aren't worth any minimal benefits.

Cochair Peter J. McDonnell, MD, highlights what this year’s conference will mean for clinicians and addresses the anticipated increased patient volume.

According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.

As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

In a presentation at the American Society for Microbiology’s annual meeting, the oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

The agreement includes rights to develop, manufacture and commercialize NOV03 in Japan for the treatment of dry eye disease.

RAFARM and BioNanoSim have entered into an agreement to create the company.

According to the company, CyclASol is preservative-free and does not contain any oils or surfactants, which can be irritating and disturbing for the tear film.

The topical drug is being tested in a multi-center, double-masked, placebo-controlled trial to treat dry eye disease (DED).

According to the company, the Preservative Freedom Coalition will put the topic of preservative-free eye care in focus through education to eye care professionals and patients.

New option a potential treatment for patients diagnosed with dry eye disease.

In a recent update, the CDC has noted an additional death, bringing the death toll up to 4, with numerous counts of vision loss across the US.

The company noted tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score or in improvement in Eye Dryness Score assessed at week 8 in subjects with dry eye disease, compared to vehicle. However, tanfanercept did demonstrate a highly statistically significant improvement on one of the secondary outcome measures, Schirmer testing of tear volume.

Ophthalmology Times reached out to members of its editorial advisory board along with ophthalmologists who specialize in dry eye for their comments on what this approval means for their patients with dry eye.

According to the companies, MIEBO is the first and only prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.

In November 2022, doctors in Cleveland diagnosed a patient with a corneal ulcer with a Pseudomona aeruginosa infection. The patient acquired the infection from tainted EzriCare eye drops months before the CDC’s February 2023 warning.

From ingredients that should not be included to ingredients that should be but are not, and improper storage and manufacturing, numerous eye drops have raised safety concerns.

Lucie Moore, BSc, in a presentation at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, said the study focused on identifying factors that could put patients at a higher risk for developing dry eye disease.

According to the company, consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile.

Instead, vitamins C and E may actually be associated with a slightly increased risk of DED.

Esen Akpek, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss ocular surface disease and the lifestyle choices that could affect eye health. As well as what The Tear Film & Ocular Surface Society is doing to promote research on the topic.

The ESSENCE-2 study showed a significantly greater reduction in the total corneal fluorescein staining (tCFS) score.

Alice Epitropoulos, MD, goes over some tips and methods to educate patients about OSD before performing any surgery.